已收盤 08-22 16:00:00 美东时间
+0.280
+4.65%
Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and lowers the price target from $42 to $25.
08-12 19:41
2025 Financial OutlookBased on its current operating plans, Karyopharm expects the following for full year 2025:Total revenue to be in the range of $140 million to $155 million. Total revenue consists of U.S. XPOVIO net
08-11 19:34
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to rep...
08-11 16:32
Karyopharm Therapeutics (NASDAQ:KPTI) is set to give its latest quarterly earni...
08-09 04:06
2025 年已经过半,裁员、削减成本,成为众多药企不得不面对的现实。据 Fierce Biotech 统计,仅在今年 7 月,就有 20 家药企宣布了裁员计划...
08-01 12:49
Karyopharm Therapeutics ( ($KPTI) ) has issued an update. Karyopharm Therapeuti...
07-11 19:47
HC Wainwright & Co. analyst Robert Burns assumes Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy rating and announces Price Target of $27.
07-11 18:15
Karat Packaging Inc. announced the pricing of an underwritten secondary offering of 1.5 million shares of its common stock by certain management team members at $27.00 per share. Underwriters have a 30-day option to purchase an additional 225,000 shares. The offering is expected to close on June 12, 2025. The Company will not receive proceeds from the sale. BofA Securities and William Blair & Company are acting as joint lead book-runners. The off...
06-11 02:15
NEWTON, Mass., June 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the...
06-03 04:05
The latest announcement is out from Karyopharm Therapeutics ( ($KPTI) ). At the...
05-30 04:53